LifeSciences BC > News > Industry News > 2014 > Biotechnology Focus Magazine – Xenon and Genentech establish new pain discovery collaboration

Print Friendly

B.C. Industry News

Biotechnology Focus Magazine – Xenon and Genentech establish new pain discovery collaboration

April 1, 2014

BIOTECHNOLOGY FOCUS

BC-biotech company Xenon Pharmaceuticals Inc. is teaming up with Genentech to discover and validate new therapeutic targets and mechanisms for treating pain.

The collaboration leverages Xenon’s Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitated spontaneous severe pain explains Dr. Simon Pimstone, president and CEO of Xenon. It’s not the first time that Xenon has teamed up with Genentech, a member company of the Roche Group. The two sides previously formed a strategic alliance  in 2012 for the discovery and development of compounds and companion diagnostics for the potential treatment of pain.

“We believe the pain market is currently under served and represents a significant commercial opportunity for our company. We look forward to working further with Genentech to seek to discover additional highly validated targets that could yield novel non-opioid based mechanisms to treat pain,” said Pimstone.

Pursuant to the terms of the new agreement, both Xenon and Genentech will own the intellectual property arising out of the collaboration. Xenon has also granted Genentech a time-limited, exclusive right of negotiation on a target-by-target basis to form joint drug discovery collaborations. Financial terms of the agreement were not disclosed.